An Introduction to Decision Analysis in the Economic Evaluation of the Prevention and Treatment of Vision-Related Diseases

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Ophthalmic Epidemiology

• Publication date

  2008-01-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1080/09286580801939346PMID 18432490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Burden of Age-Related Macular Degeneration

  2012cited by this paper
• Recent Developments in Decision-Analytic Modelling for Economic Evaluation

  2012cited by this paper
• The impact of anchor point on utilities for 5 common ophthalmic diseases.

  2008cited by this paper
• LXIII Edward Jackson Memorial Lecture: Eye care: dollars and sense.

  2007cited by this paper
• Costs of interventions for visual impairment.

  2007cited by this paper
• Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss.

  2007cited by this paper
• Methods for the economic evaluation of health care programmes, 3rd ed

  2006cited by this paper
• Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.

  2006cited by this paper
• The Annual Cost of Dry Eye Syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom Among Patients Managed by Ophthalmologists

  2006cited by this paper
• Ranibizumab (Lucentis) for macular degeneration.

  2006cited by this paper
• Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.

  2006cited by this paper
• Costs and Utilization of End-stage Glaucoma Patients Receiving Visual Rehabilitation Care: A US Multisite Retrospective Study

  2006cited by this paper
• The effect of autologous serum eye drops in the treatment of severe dry eye disease: a prospective randomized case-control study.

  2005cited by this paper
• The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.

  2005cited by this paper
• Economic cost of cataract surgery procedures in an established eye care centre in Southern India

  2004cited by this paper
• Value-based medicine and ophthalmology: an appraisal of cost-utility analyses.

  2004cited by this paper
• The Economic Burden of Dry Eye: A Conceptual Framework and Preliminary Assessment

  2004cited by this paper
• Value-based medicine and vitreoretinal diseases

  2004cited by this paper
• Cost of treating preventable minor ocular injuries in Rijeka, Croatia.

  2004cited by this paper
• Health technology assessment and its influence on health-care priority setting

  2004cited by this paper
• It's the prices, stupid: why the United States is so different from other countries.

  2003cited by this paper
• Cost‐effectiveness of ocular interventions

  2003cited by this paper
• CME REVIEW: A COST‐UTILITY ANALYSIS OF LASER PHOTOCOAGULATION FOR EXTRAFOVEAL CHOROIDAL NEOVASCULARIZATION

  2003cited by this paper
• Cost-utility analysis of cataract surgery in the second eye.

  2003cited by this paper
• Cost of Glaucoma in Canada: Analyses Based on Visual Field and Physician's Assessment

  2003cited by this paper
• Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.

  2003cited by this paper
• Health care economic analyses and value-based medicine.

  2003cited by this paper
• A cost-utility analysis of therapy for amblyopia.

  2002cited by this paper
• A cost-utility analysis of interventions for severe proliferative vitreoretinopathy.

  2002cited by this paper
• Glaucoma Patients' Assessment of Their Visual Function and Quality of Life

  2002cited by this paper
• Incremental cost-effectiveness of initial cataract surgery.

  2002cited by this paper
• The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy

  2001cited by this paper
• The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

  2001cited by this paper
• Representing uncertainty: the role of cost-effectiveness acceptability curves.

  2001cited by this paper
• The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis.

  2000cited by this paper
• Vision and quality-of-life.

  1999cited by this paper
• Cost Effectiveness in Health and Medicine.

  1998cited by this paper
• Use of economic evaluation guidelines: 2 years' experience in Canada.

  1998cited by this paper
• Direct costs of glaucoma management following initiation of medical therapy

  1998cited by this paper
• Primer on Medical Decision Analysis: Part 2—Building a Tree

  1997cited by this paper
• Use of Influence Diagrams to Structure Medical Decisions

  1997cited by this paper
• Confidence intervals for cost-effectiveness ratios: a comparison of four methods.

  1997cited by this paper
• Primer on Medical Decision Analysis: Part 1—Getting Started

  1997cited by this paper
• On valuing morbidity, cost-effectiveness analysis, and being rude.

  1997cited by this paper
• Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

  1996cited by this paper
• Utilities and Quality-Adjusted Life Years

  1989cited by this paper
• Cost effectiveness of current approaches to the control of retinopathy in type I diabetics.

  1989cited by this paper
• Methods for the economic evaluation of health care programmes

  1987cited by this paper
• Social preferences for health states: An empirical evaluation of three measurement techniques

  1976cited by this paper
• The formulation and evolution of the Health Maintenance Organization policy, 1970-1973.

  1976cited by this paper

• Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.

  2023cites this paper
• Economic evaluation of HIV testing options for low-prevalence high-income countries: a systematic review

  2021cites this paper
• Health Economic Analysis in Glaucoma

  2020cites this paper
• Health economic evaluation in ophthalmology

  2020cites this paper
• Patient-reported Outcomes, Functional Assessment, and Utility Values in Glaucoma

  2019cites this paper
• Socioeconomic Cost of Diabetic Retinopathy and Therapy

  2017cites this paper
• Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges

  2016cites this paper
• Does the type of treatment have an influence on utility values in a glaucoma population?

  2015cites this paper
• Economics of Glaucoma Care

  2015cites this paper
• Utility values for glaucoma in Brazil and their correlation with visual function

  2014cites this paper
• Utility values for glaucoma in Brazil and their correlation with visual function

  2014cites this paper
• Is it time to move beyond the QALY in vision research?

  2014cites this paper
• Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy.

  2013cites this paper
• Decision and Simulation Modeling in Systematic Reviews

  2013cites this paper
• Quality of Life in Glaucoma Patients

  2013cites this paper
• The cost of glaucoma care provided to Medicare beneficiaries from 2002 to 2009.

  2013cites this paper
• Development of a decision-analytic model for the application of STR-based provenance testing of transrectal prostate biopsy specimens.

  2012cites this paper
• Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

  2012cites this paper
• A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma

  2012cites this paper
• Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia

  2012cites this paper
• The development of a decision analytic model of changes in mean deviation in people with glaucoma: the COA model.

  2012cites this paper
• Computational Decision Support Systems and Diagnostic Tools in Ophthalmology: A Schematic Survey

  2011cites this paper
• Cost-effectiveness of screening for open angle glaucoma in developed countries

  2011cites this paper
• The lifetime economic burden of keratoconus: a decision analysis using a markov model.

  2011cites this paper
• Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension

  2010cites this paper
• The cost-effectiveness of treatment of age-related macular degeneration: a review.

  2009cites this paper